Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). (Q46657782)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

main subject

phase II clinical trial

0 references

11

David R Gandara

1 reference

24 December 2017

Primo N Lara

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Kari Chansky

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Angela M Davies

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Wilbur A Franklin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Paul H Gumerlock

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Perry P Guaglianone

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

James N Atkins

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Nichole Farneth

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Philip C Mack

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

John J Crowley

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

David R Gandara

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 November 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

Journal of Thoracic Oncology

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

996-1001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

Treatment of recurrent small cell lung cancer

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931633-6

7 January 2021

Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931633-6

7 January 2021

Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931633-6

7 January 2021

Second-line chemotherapy for relapsed small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931633-6

7 January 2021

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931633-6

7 January 2021

Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931633-6

7 January 2021

Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931633-6

7 January 2021

Role of Bcl-2, Bax, and Bak in spontaneous apoptosis and proliferation in neuroendocrine lung tumors: immunohistochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931633-6

7 January 2021

Bcl-2 as a Target for Overcoming Chemoresistance in Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931633-6

7 January 2021

Bcl-2 oncoprotein expression is increased especially in the portion of small cell carcinoma within the combined type of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931633-6

7 January 2021

Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931633-6

7 January 2021

Abnormalities of apoptotic and cell cycle regulatory proteins in distinct histopathologic components of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931633-6

7 January 2021

Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931633-6

7 January 2021

Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931633-6

7 January 2021

Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931633-6

7 January 2021

Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931633-6

7 January 2021

10.1016/S1556-0864(15)31633-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409985%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference